

**ANNEX I**  
**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Equilis West Nile suspension for injection for horses

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 1 ml contains:

### Active substance:

Inactivated chimeric flavivirus strain YF-WN  $\geq 492 \text{ AU}^1$

### Adjuvant:

Iscom-Matrix containing:

Purified saponin 250 micrograms

Cholesterol 83 micrograms

Phosphatidylcholine 42 micrograms

<sup>1</sup> Antigenic units determined by ELISA.

For the full list of excipients, see section 6.1.

## 3. PHARMACEUTICAL FORM

Suspension for injection.

Opalescent suspension.

## 4. CLINICAL PARTICULARS

### 4.1 Target species

Horses.

### 4.2 Indications for use, specifying the target species

Active immunisation of horses against West Nile virus (WNV) to reduce clinical signs of disease and lesions in the brain and to reduce viraemia.

Onset of immunity: 2 weeks after primary vaccination course of two injections.

Duration of immunity: 12 months.

### 4.3 Contraindications

None.

### 4.4 Special warnings for each target species

Vaccinate healthy animals only.

### 4.5 Special precautions for use

Special precautions for use in animals

Not applicable.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

#### **4.6 Adverse reactions (frequency and seriousness)**

##### In laboratory studies and field trials:

After vaccination a mild transient swelling may very commonly develop at the injection site (max. 3 cm in diameter). This swelling normally resolves within 1 to 5 days. A mild body temperature increase (max. 1.5 °C) may very commonly occur for 1 to 2 days.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

#### **4.7 Use during pregnancy, lactation or lay**

Can be used during pregnancy and lactation.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

#### **4.9 Amounts to be administered and administration route**

Intramuscular use.

##### Vaccination schedule:

Administer one dose (1 ml) by intramuscular injection, according to the following schedule:

*Primary vaccination:* first injection from 6 months of age onwards, second injection 3 to 5 weeks later.

*Revaccination:* a yearly booster injection of one dose (1 ml) should be sufficient to achieve a reduction of fever, lesions in the brain and viraemia.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

Following the administration of a double dose of vaccine, no side-effects other than those described under section 4.6 have been observed.

#### **4.11 Withdrawal period(s)**

Zero days.

### **5. IMMUNOLOGICAL PROPERTIES**

Pharmacotherapeutic group: Immunologicals for Equidae, inactivated viral vaccines.

ATCvet code: QI05AA10.

The vaccine stimulates active immunity against West Nile virus in horses.

## **6. PHARMACEUTICAL PARTICULARS**

### **6.1 List of excipients**

Sodium chloride  
Potassium chloride  
Disodium hydrogen phosphate dihydrate  
Potassium dihydrogen phosphate  
Water for injections

### **6.2 Major incompatibilities**

Do not mix with any other veterinary medicinal product.

### **6.3 Shelf life**

Shelf life of the veterinary medicinal product as packaged for sale: 1 year.

### **6.4 Special precautions for storage**

Store in a refrigerator (2 °C – 8 °C).  
Do not freeze.  
Protect from light.

### **6.5 Nature and composition of immediate packaging**

Type I glass vials of 1 ml (1 dose) closed with a halogenobutyl rubber stopper and sealed with an aluminium cap.

Type I glass pre-filled syringes of 1ml (1 dose), containing a plunger with a halogenobutyl end and closed with a halogenobutyl stopper.

#### Package sizes:

Cardboard box with 10 glass vials of 1 ml (1 dose).  
Plastic box with 10 glass vials of 1 ml (1 dose).  
Cardboard box with 5 or 10 pre-filled syringes of 1 ml (1 dose).  
Plastic box with 5 or 10 pre-filled syringes of 1 ml (1 dose).

Not all pack sizes may be marketed.

### **6.6 Special precautions for the disposal of unused veterinary medicinal products or waste materials derived from the use of such products**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Intervet International B.V.  
Wim de Körverstraat 35

5831 AN Boxmeer  
The NETHERLANDS

**8. MARKETING AUTHORISATION NUMBER(S)**

EU/2/13/151/0001-0003

**9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION**

Date of first authorisation: 06/06/2013.

Date of last renewal:

**10. DATE OF REVISION OF THE TEXT**

{MM/YYYY}

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu/>).

**PROHIBITION OF SALE, SUPPLY AND/OR USE**

Any person intending to manufacture, import, possess, sell, supply and use Equilis West Nile must first consult the relevant Member State's competent authority on the current vaccination policies, as these activities may be prohibited in a Member State on the whole or part of its territory pursuant to national legislation.

## **ANNEX II**

- A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**
- B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**
- C. STATEMENT OF THE MRLs**

**A. MANUFACTURER OF THE BIOLOGICAL ACTIVE SUBSTANCE AND  
MANUFACTURER RESPONSIBLE FOR BATCH RELEASE**

Name and address of the manufacturer of the biological active substance

Intervet International B.V.  
Wim de Körverstraat 35  
5831AN Boxmeer  
The NETHERLANDS

Name and address of the manufacturer responsible for batch release

Intervet International B.V.  
Wim de Körverstraat 35  
5831AN Boxmeer  
The NETHERLANDS

**B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE**

Veterinary medicinal product subject to prescription.

According to Article 71 of Directive 2001/82/EC of the European Parliament and of the Council as amended, a Member State may, in accordance with its national legislation, prohibit the manufacture, import, possession, sale, supply and/or use of immunological veterinary medicinal products on the whole or part of its territory if it is established that:

- a) the administration of the product to animals will interfere with the implementation of a national programme for the diagnosis, control or eradication of animal diseases, or will cause difficulties in certifying the absence of contamination in live animals or in foodstuffs or other products obtained from treated animals.
- b) the disease to which the product is intended to confer immunity is largely absent from the territory in question.

**C. STATEMENT OF THE MRLs**

The active substance being a principle of biological origin intended to produce active immunity is not within the scope of Regulation (EC) No 470/2009.

The excipients (including adjuvants) listed in section 6.1 of the SPC are either allowed substances for which table 1 of the annex to Commission Regulation (EU) No 37/2010 indicates that no MRLs are required or considered as not falling within the scope of Regulation (EC) No 470/2009 when used as in this veterinary medicinal product.

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**

## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

**BOX**

Cardboard box or plastic box with 10 vials of 1 ml, or 5 or 10 pre-filled syringes of 1 ml

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Equilis West Nile suspension for injection for horses

**2. STATEMENT OF ACTIVE SUBSTANCES**

1 ml:  
Inactivated chimeric flavivirus strain YF-WN  $\geq 492$  AU  
Iscom-Matrix

**3. PHARMACEUTICAL FORM**

Suspension for injection.

**4. PACKAGE SIZE**

10 vials x 1 dose  
5 pre-filled syringes x 1 dose  
10 pre-filled syringes x 1 dose

**5. TARGET SPECIES**

Horses

**6. INDICATION(S)**

**7. METHOD AND ROUTE(S) OF ADMINISTRATION**

Read the package leaflet before use.  
Intramuscular use.

**8. WITHDRAWAL PERIOD(S)**

Withdrawal period: Zero days.

**9. SPECIAL WARNING(S), IF NECESSARY**

Read the package leaflet before use.

**10. EXPIRY DATE**

EXP {month/year}

**11. SPECIAL STORAGE CONDITIONS**

Store in a refrigerator. Do not freeze. Protect from light.

**12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY**

Disposal: read package leaflet.

**13. THE WORDS “FOR ANIMAL TREATMENT ONLY” AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable**

For animal treatment only. To be supplied only on veterinary prescription.

**14. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER**

Intervet International B.V.  
Wim de Körverstraat 35  
5831 AN Boxmeer  
The NETHERLANDS

**16. MARKETING AUTHORISATION NUMBER(S)**

EU/2/13/151/0001 (10 vials)  
EU/2/13/151/0002 (5 pre-filled syringes)  
EU/2/13/151/0003 (10 pre-filled syringes)

**17. MANUFACTURER’S BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

**LABEL**

**1 ml vial, 1 ml pre-filled syringe**

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Equilis West Nile [*a clear pictogram of a horse*]

**2. QUANTITY OF THE ACTIVE SUBSTANCE(S)**

**3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES**

1 ml (1 dose)

**4. ROUTE(S) OF ADMINISTRATION**

IM

**5. WITHDRAWAL PERIOD(S)**

Withdrawal period: Zero days.

**6. BATCH NUMBER**

Lot {number}

**7. EXPIRY DATE**

EXP {month/year}

**8. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**B. PACKAGE LEAFLET**

**PACKAGE LEAFLET:**  
**Equilis West Nile suspension for injection for horses**

**1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT**

Marketing authorisation holder and manufacturer responsible for batch release:

Intervet International B.V.  
Wim de Körverstraat 35  
5831 AN Boxmeer  
The NETHERLANDS

**2. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Equilis West Nile suspension for injection for horses

**3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)**

Each dose of 1 ml contains:

Inactivated chimeric flavivirus strain YF-WN	≥ 492 AU <sup>1</sup>
Iscom-Matrix containing:	
Purified saponin	250 micrograms
Cholesterol	83 micrograms
Phosphatidylcholine	42 micrograms

<sup>1</sup> Antigenic units

Opalescent suspension.

**4. INDICATION(S)**

Active immunisation of horses against West Nile virus (WNV) to reduce clinical signs of disease and lesions in the brain and to reduce viraemia.

Onset of immunity: 2 weeks after primary vaccination course of two injections.

Duration of immunity: 12 months.

**5. CONTRAINDICATIONS**

None.

**6. ADVERSE REACTIONS**

In laboratory studies and field trials:

After vaccination a mild transient swelling may very commonly develop at the injection site (max. 3 cm in diameter). This swelling normally resolves within 1 to 5 days. A mild body temperature increase (max. 1.5 °C) may very commonly occur for 1 to 2 days.

The frequency of adverse reactions is defined using the following convention:

- very common (more than 1 in 10 animals treated displaying adverse reaction(s))

- common (more than 1 but less than 10 animals in 100 animals treated )
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).

If you notice any side effects, even those not already listed in this package leaflet or you think that the medicine has not worked, please inform your veterinary surgeon.

## **7. TARGET SPECIES**

Horses.

## **8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION**

Intramuscular use.

### Vaccination schedule:

Administer one dose (1 ml) by intramuscular injection, according to the following schedule:

*Primary vaccination:* first injection from 6 months of age onwards, second injection 3 to 5 weeks later.

*Revaccination:* a yearly booster injection of one dose (1 ml) should be sufficient to achieve a reduction of fever, lesions in the brain and viraemia.

## **9. ADVICE ON CORRECT ADMINISTRATION**

None.

## **10. WITHDRAWAL PERIOD(S)**

Zero days.

## **11. SPECIAL STORAGE PRECAUTIONS**

Keep out of the sight and reach of children.

Store in a refrigerator (2 °C – 8 °C). Do not freeze. Protect from light.

Do not use this veterinary medicinal product after the expiry date which is stated on the label.

## **12. SPECIAL WARNING(S)**

### Special warnings for each target species:

Vaccinate healthy animals only.

### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

### Pregnancy and lactation:

Can be used during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction:

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Major incompatibilities:

Do not mix with any other veterinary medicinal product.

**13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY**

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

**14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED**

{DD/MM/YYYY}

Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency (<http://www.ema.europa.eu/>).

**15. OTHER INFORMATION**

The vaccine stimulates active immunity against West Nile virus in horses.

Package sizes:

Cardboard box with 10 glass vials of 1 ml (1 dose).

Plastic box with 10 glass vials of 1 ml (1 dose).

Cardboard box with 5 or 10 pre-filled syringes of 1 ml (1 dose).

Plastic box with 5 or 10 pre-filled syringes of 1 ml (1 dose).

Not all pack sizes may be marketed.

**ANNEX IV**

**GROUNDS FOR ONE ADDITIONAL RENEWAL**

Due to the recent placing on the market of the veterinary medicinal product Equilis West Nile and the consequently limited post-marketing safety information, the CVMP at their meeting on 16-18 January 2018 decided that one five-year renewal is required.